Modality
ADC
MOA
TYK2i
Target
CFTR
Pathway
NF-κB
Urothelial CaGBMOvarian Ca
Development Pipeline
Preclinical
~Aug 2009
→ ~Nov 2010
Phase 1
~Feb 2011
→ ~May 2012
Phase 2
~Aug 2012
→ ~Nov 2013
Phase 3
~Feb 2014
→ ~May 2015
NDA/BLA
~Aug 2015
→ ~Nov 2016
Approved
Feb 2017
→ Mar 2030
ApprovedCurrent
NCT06823022
911 pts·Ovarian Ca
2022-06→2025-01·Recruiting
NCT05752937
2,076 pts·GBM
2020-12→2030-03·Not yet recruiting
NCT06221742
1,316 pts·GBM
2017-02→TBD·Recruiting
4,303 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2025-01-271.2y agoPh3 Readout· Ovarian Ca
2030-03-164.0y awayPh3 Readout· GBM
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Recruit…
Approved
Not yet…
Approved
Recruit…
Catalysts
Ph3 Readout
2025-01-27 · 1.2y ago
Ovarian Ca
Ph3 Readout
2030-03-16 · 4.0y away
GBM
RecruitingNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06823022 | Approved | Ovarian Ca | Recruiting | 911 | LiverFat |
| NCT05752937 | Approved | GBM | Not yet recr... | 2076 | PASI75 |
| NCT06221742 | Approved | GBM | Recruiting | 1316 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 |